Citius Oncology earnings were -$46.1M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest CTOR earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$8.9M, down 66.5% from last quarter. For the last reported fiscal year 2025 ending Sep 30, 2025, CTOR reported annual earnings of -$24.8M, with 17.1% growth. The next CTOR earnings date is Dec 22, 2026.
What were Citius Oncology's earnings last quarter?
On CTOR's earnings call on Aug 18, 2026, Citius Oncology (NASDAQ: CTOR) reported Q2 2026 earnings per share (EPS) of -$0.08, up 0% year over year. Total CTOR earnings for the quarter were -$8.92 million. In the same quarter last year, Citius Oncology's earnings per share (EPS) was -$0.08.
The next CTOR earnings call is Dec 22, 2026. Add CTOR to your watchlist to be reminded of Citius Oncology's next earnings date.
What was CTOR's earnings growth in the past year?
As of Citius Oncology's earnings date in Aug 18, 2026, Citius Oncology's earnings has grown year over year. CTOR earnings in the past year totalled -$46.06 million.
Is Citius Oncology profitable or losing money?
As of the last Citius Oncology earnings report, Citius Oncology is currently losing money. Citius Oncology's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$46.06 million, a 73.32% increase year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.